Search Results - "Rifkin, R.M"

60 EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE by Savona, M.R, Kolibaba, K, Conkling, P, Kingsley, E.C, Becerra, C, Morris, J.C, Rifkin, R.M, Laille, E, Kellerman, A, Ukrainskyj, S.M, Dong, Q, Skikne, B.S

Get full text

Clinical Outcomes in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) and t(4;14) in the Connect MM® Registry by Shah, J.J, Narang, M, Abonour, R, Mehta, J, Terebelo, H, Gasparetto, C.J, Toomey, K, Hardin, J.W, Srinivasan, S, Larkins, G, Nagarwala, Y, Rifkin, R.M

Get full text

Change In Patient-Reported Outcomes During The First Year Post-Diagnosis Of Multiple Myeloma by Pashos, C.L, Shah, J.J, Terebelo, H.R, Durie, B.G, Abonour, R, Gasparetto, C, Mehta, J, Narang, M, Thomas, S, Toomey, K, Swern, A, Sullivan, K.A, Street, T.K, Khan, Z.M, Nourbakhsh, A, Hardin, J.W, Wildes, T.M, Rifkin, R.M

Get full text

PCN142 Association of Health-Related Quality of Life Among Patients With Multiple Myeloma With Insurance Coverage by Pashos, C.L, Durie, B.G, Rifkin, R.M, Abonour, R, Fonseca, R, Gasparetto, C, Mehta, J, Narang, M, Shah, J.J, Terebelo, H.R, Thomas, S, Toomey, K, Swern, A.S, Harding, G, Yu, R, Sullivan, K.A, Street, T.K, Khan, Z.M

Get full text

PCN117 ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ISS STAGE AND ECOG STATUS IN MULTIPLE MYELOMA by Pashos, C.L, Durie, B.G, Mehta, J, Toomey, K, Terebelo, H.R, Abonour, R, Fonseca, R, Gasparetto, C, Narang, M, Rifkin, R.M, Shah, J.J, Sullivan, K.A, Street, T.K, Khan, Z.M

Get full text

Real-World Utilization of Radiation Therapy (RT) in Multiple Myeloma (MM): An Analysis of the Connect® MM Registry by Ballas, L.K., Ailawadhi, S., Narang, M., Gasparetto, C.J., Lee, H., Hardin, J.W., Durie, B.G.M., Toomey, K., Omel, J., Wagner, L.I., Abonour, R., Terebelo, H.R., Joshi, P., Yu, E., Liu, L., Rifkin, R.M., Jagannath, S.

Get full text

Hodgkin's disease following solid organ transplantation by Bierman, P. J., Vose, J. M., Langnas, A. N., Rifkin, R. M., Hauke, R. J., Smir, B. N., Greiner, T. C.

“…Background: The incidence of second malignancies is markedly increased following transplantation of solid organs. However, the development of Hodgkin's disease…”
Get full text

Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry by Abonour, R., Rifkin, R.M., Gasparetto, C., Toomey, K., Durie, B.G.M., Hardin, J.W., Terebelo, H.R., Jagannath, S., Narang, M., Ailawadhi, S., Srinivasan, S., Kitali, A., Agarwal, A., Wagner, L.

Get full text

PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA) by Rifkin, R.M., Yimer, H.A., Noga, S.J., Manda, S., Birhiray, R., Yasenchak, C., Lyons, R., Kelly, P., Chojnicki, E., Whidden, P., Wang, B., Demers, B., Dollar, L., Boccia, R.

“…Background: LTPI improves outcomes in NDMM vs non‐proteasome inhibitor (PI)–based therapy. However, the efficacy improvements seen in clinical trials are often…”
Get full text

PS1384 TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY by Jagannath, S., Narang, M., Ailawadhi, S., Rifkin, R.M., Terebelo, H.R., Toomey, K., Durie, B.G., Hardin, J.W., Gasparetto, C.J., Wagner, L., Omel, J., Srinivasan, S., Kitali, A., Agarwal, A., Abonour, R.

“…Please indicate where the has been published before: Jagannath S, et al. Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on…”
Get full text

PCN103 - Change In Patient-Reported Outcomes During The First Year Post-Diagnosis Of Multiple Myeloma by Pashos, C.L., Shah, J.J., Terebelo, H.R., Durie, B.G., Abonour, R., Gasparetto, C., Mehta, J., Narang, M., Thomas, S., Toomey, K., Swern, A., Sullivan, K.A., Street, T.K., Khan, Z.M., Nourbakhsh, A., Hardin, J.W., Wildes, T.M., Rifkin, R.M.

Get full text

A Randomized Placebo Controlled Phase II Trial of Prevention of Severe Oral Mucositis Using Single Dose Velafermin in Patients Receiving Myeloablative Therapy and Autologous Hematopoietic Stem Cell Transplant (AHSCT) by Schuster, Michael W., Mehta, J., Waller, E.K., Rifkin, R.M., Micallef, I., Hurd, D., Parekh, S., Hari, P., Skikne, B.S., Shea, T.C., Frei-Lahr, D.A., Abonour, R., Freytes, C.O., Pineiro, L., Halvorsen, Y.C., Anaissie, E.J.

“…Oral mucositis (OM) is a commonly occurring side effect in patients (pts) undergoing AHSCT. Velafermin, recombinant human fibroblast growth factor-20, is under…”
Get full text

Open-label, randomized comparison of dolasetron versus ondansetron for prevention of nausea and vomiting during high-dose chemotherapy and stem cell transplantation by Mandanas, R.A., Beveridge, R.A., Rifkin, R.M., Wallace, H.J., Greenspan, A., Spitzer, G., Guo, H., Asmar, L.

Get full text

Phase II trial of GM-CSF as maintenance therapy post–autologous peripheral blood stem cell transplantation in multiple myeloma by Mandanas, R.A., Beveridge, R., Rifkin, R.M., Greenspan, A.R., Orloff, G.J., Klein, L.M., Rauch, M.A., Boehm, K.A., Zhan, F., Asmar, L.

Get full text

Effects of in vivo and in vitro alcohol administration on insulin binding and glycogenesis in isolated rat hepatocytes by Rifkin, R M, Todd, W W, Toothaker, D R, Sussman, A, Trowbridge, M, Draznin, B

“…Chronic alcohol ingestion was accompanied by a mild decrease in insulin binding (from 11.7 to 8.9% per 1 X 10(6) cells) that was accounted for by changes in…”
Get more information